Novel CDK12/13 Inhibitors AU-15506 and AU-16770 Are Potent Anti-Cancer Agents in EGFR Mutant Lung Adenocarcinoma with and without Osimertinib Resistance
Tapan K. Maity(Center for Cancer Research), Udayan Guha(Center for Cancer Research)
Cited by 9
Related Papers
NAD metabolism modulates inflammation and mitochondria function in diabetic kidney disease
|Journal of Biological Chemistry|2023|71
EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models
|Oncotarget|2016|50
Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response
|Molecular Case Studies|2016|24
Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V
|bioRxiv (Cold Spring Harbor Laboratory)|2018|2